Have a personal or library account? Click to login
Oncolytic Adenovirus-Based Immunotherapy for Malignant Mesothelioma: Preclinical Advances and Future Perspectives Cover

Oncolytic Adenovirus-Based Immunotherapy for Malignant Mesothelioma: Preclinical Advances and Future Perspectives

Open Access
|Jul 2025

Figures & Tables

Summary of the key features of AdV-D24-ICOSL-CD40L and Ad5/3-D24-GM-CSF_

Oncolytic AdenovirusTumor SelectivityTransgenesStudiesMajor results
AdV5/3-D24-ICOSL-CD40LYes (E1A deletion)ICOSL and CD40L for enhanced T-cell costimulationPreclinical mesothelioma models (both in vitro and in vivo)Safety profile, enhances efficacy, ICD, T-cell infiltration
Ad5/3-D24-GM-CSF (ONCOS-102)GM-CSF for improved antigen presentationPhase I/II in mesothelioma (NCT02963831)T-cell infiltration, safety profile, improved efficacy
DOI: https://doi.org/10.2478/am-2025-0004 | Journal eISSN: 2545-3149 | Journal ISSN: 0079-4252
Language: English, Polish
Page range: 46 - 50
Submitted on: Mar 23, 2025
|
Accepted on: May 30, 2025
|
Published on: Jul 8, 2025
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2025 Mariangela Garofalo, Monika Staniszewska, Stefano Salmaso, Paolo Caliceti, Lukasz Kuryk, published by Polish Society of Microbiologists
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.